Anthropic

A new antitrust lawsuit targets Anthropic, OpenAI, xAI and Google, alleging the AI companies agreed among themselves to slow the pace of AI development. Plaintiffs argue the alleged plan had been in motion for months before the companies publicly described any such agreement as self-serving. If the claims hold up, the case could become a major test of how competition law applies to coordination among leading AI labs.

Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.

Anthropic says its Claude AI helped identify a previously unknown gene-editing enzyme, a claim that, if verified, would mark a significant moment for AI-driven scientific discovery. However, the finding has not yet been independently confirmed by the scientific community, and experts are urging caution until the results are peer-reviewed or replicated in the lab.

A new episode of the All-In Podcast covers mounting speculation that Anthropic's planned IPO could be at risk, alongside discussion of Meta's Muse gaining popularity, falling token prices, open source models gaining market share, and renewed concerns about AI alignment failures. The panel weighs what these shifts mean for the competitive balance among leading AI companies.

OpenAI and Anthropic have found that AI safety incidents occur at a scale well beyond what either company has previously disclosed publicly, according to a report picked up by technology news outlets. The finding suggests internal monitoring of model failures and misuse reveals more problems than companies currently share with the public.